Pharmaceutical - Financial, Pfizer


Current filters:


Popular Filters

1 to 25 of 33 results

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023


In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition


US pharma giant Pfizer, which is aggressively pursuing a takeover of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceutical

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India


Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…


Pfizer shares gain despite lower sales and profits

Pfizer shares gain despite lower sales and profits


US pharma giant Pfizer reported fourth-quarter and full-year 2013 financial results that beat consensus…


Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019


The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms


Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

New Zealand views addition of rotavirus, varicella vaccines to national immunization schedule


A vaccine for the gastric infection rotavirus and protection from varicella for the most vulnerable people…

FinancialHealthcareNew ZealandPfizerPharmaceuticalPrevenarVaccines

Pfizer revenues down as patent losses hit sales

Pfizer revenues down as patent losses hit sales


Global pharma giant Pfizer has said worldwide sales fell 2% to $12.6 billion, hurt by generic competition,…

AriceptEliquisEnbrelFinancialLipitorNorth AmericaPfizerPharmaceuticalRebifSpiriva

Karo Bio gets first milestone in Pfizer collaboration


Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Repligen gets first milestone under SMA deal with Pfizer


USA-based Repligen (Nasdaq: RGEN) says it has received a $1 million milestone payment from global drugs…

FinancialLicensingPfizerPharmaceuticalRare diseasesRepligen

TVM Life Science Ventures invests in Ixchelsis


Canada-based TVM Life Science Ventures VII has announced the fund's second investment, with Ixchelsis…

Eli LillyFinancialIX-01IxchelsisMen's HealthPfizerPharmaceuticalResearch

Pfizer legacy company agrees near half billion dollar settlement with DoJ


Wyeth Pharmaceuticals, a US pharma rival acquired by US behemoth Pfizer (NYSE:PFE) in 2009, has agreed…

FinancialImmunologicalsLegalMarkets & MarketingNorth AmericaPfizerPharmaceuticalRapamuneWyeth

Pfizer beats forecasts, as 2nd-qtr earnings rocket on asset sale


Second-quarter 2013 net income at US pharma behemoth Pfizer (NYSE: PFE) leapt more than four-fold, helped…


Pfizer to split-off remaining 80% interest in Zoetis


Zoetis Inc (Nasdaq: ZTS), the animal health business of which US pharma behemoth Pfizer (NYSE: PFE) spun…

FinancialMergers & AcquisitionsPfizerPharmaceuticalZoetis

Pfizer 1st-qtr 2013 disappoints, despite near 54% leap in net income


US drugs behemoth Pfizer's (NYSE: PFE) shares fell 4.5% to $29.07 by close of trading in New York yesterday…


Zoetis IPO caps strong month for life sciences financings, says Burrill & Co


Life sciences financing activity got a strong start in the New Year as companies raised $10.3 billion…

AllerganBiotechnologyFinancialMAP PharmaceuticalsMergers & AcquisitionsPfizerPharmaceuticalZoetis

Pfizer's 4th-qtr beats forecasts, benefitting from Nutrition business sale


Global drugs behemoth Pfizer (NYSE: PFE) reported better-than-expected fourth-quarter 2012 financial…


Pfizer's Zoetis spin-off could raise $12 billion; BGI-Shenzhen updates on Complete Genomics deal


Pfizer (NYSE: PFE), the world's largest drugmaker by sales, which has previously said it is spinning…

BGI-ShenzhenBiotechnologyComplete GenomicsFinancialMergers & AcquisitionsPfizerPharmaceuticalZoetis

Pfizer 3rd-qtr profits slump on lower than expected sales; EU says "no" to Gaucher drug


US pharma behemoth Pfizer (NYSE: PFE) saw it shares fall 1.1% to $24.59 in morning trading yesterday,…

EuropeFinancialPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationtaliglucerase

Milestone payments for Epizyme and Antares Pharma


Privately-held US biotech startup Epizyme says it has received a$4 million in milestone payments from…

Antares PharmaEpizymeFinancialGlaxoSmithKlineLicensingOncologyPfizerPharmaceuticalResearch

AstraZeneca to get $250 million-plus from OTC Nexium deal with Pfizer


Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has entered into an agreement with Pfizer (NYSE:…


Pfizer in $60 million settlement over bribery charges


US drugs behemoth Pfizer (NYSE: PFE) said yesterday that it has agreed to pay a total of $60 million…

Asia-PacificEuropeFinancialLegalMarkets & MarketingPfizerPharmaceuticalWyeth

1 to 25 of 33 results

Back to top